| Assessment Status | NCPE Assessment Process Complete |
| HTA ID | - |
| Drug | Apremilast |
| Brand | Otezla® |
| Indication | Alone or in combination with DMARDs, for the treatment of active PsA in adult patients who have had an inadequate response or who have been intolerant to a prior DMARD therapy. |
| Assessment Process | |
| Rapid review commissioned | 24/02/2015 |
| Rapid review completed | 03/04/2015 |
| Rapid review outcome | Full Pharmacoeconomic Evaluation Recommended |
| Full submission received from Applicant | 01/09/2015 |
| NCPE assessment completed | 29/04/2016 |
| NCPE assessment outcome | Reimbursement Not Recommended at the Submitted Price. |
The HSE has approved reimbursement following confidential price negotiations October 2017.
